Landiolol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Landiolol
Accession Number
DB12212
Type
Small Molecule
Groups
Investigational
Description

Landiolol has been used in trials studying the treatment of Pharmacokinetics/Dynamics Study.

Structure
Thumb
Synonyms
Not Available
External IDs
AOP-200704 / AOP200704 / LDLL-600 / LDLL600 / ONO-1101
Product Ingredients
IngredientUNIICASInChI Key
Landiolol HydrochlorideG8HQ634Y17144481-98-1DLPGJHSONYLBKP-IKGOIYPNSA-N
Categories
UNII
62NWQ924LH
CAS number
133242-30-5
Weight
Average: 509.6
Monoisotopic: 509.273715228
Chemical Formula
C25H39N3O8
InChI Key
WMDSZGFJQKSLLH-RBBKRZOGSA-N
InChI
InChI=1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22+/m0/s1
IUPAC Name
[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-{4-[(2S)-2-hydroxy-3-({2-[(morpholine-4-carbonyl)amino]ethyl}amino)propoxy]phenyl}propanoate
SMILES
CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Landiolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Landiolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Landiolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Landiolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Landiolol.Approved, Experimental, Investigational
AcepromazineLandiolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Landiolol.Approved
AcetohexamideLandiolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Landiolol is combined with Acetylcholine.Approved
AcetyldigitoxinLandiolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinLandiolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Landiolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Landiolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Landiolol.Experimental, Investigational
AlaproclateThe serum concentration of Landiolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Landiolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Landiolol.Approved, Illicit
AlfuzosinLandiolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Landiolol.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Landiolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Landiolol.Approved
AmiodaroneThe therapeutic efficacy of Landiolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Landiolol.Vet Approved
AmitriptylineLandiolol may increase the orthostatic hypotensive activities of Amitriptyline.Approved
AmobarbitalThe serum concentration of Landiolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Landiolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapineLandiolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Landiolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Landiolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Landiolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Landiolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Landiolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Landiolol is combined with Arecoline.Experimental
AripiprazoleLandiolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
AsenapineLandiolol may increase the orthostatic hypotensive activities of Asenapine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Landiolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Landiolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Landiolol.Approved, Investigational
BarbexacloneThe serum concentration of Landiolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Landiolol can be decreased when it is combined with Barbital.Illicit
BendazacBendazac may decrease the antihypertensive activities of Landiolol.Experimental
BenorilateBenorilate may decrease the antihypertensive activities of Landiolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Landiolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Landiolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Landiolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
BevantololLandiolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Landiolol.Experimental
BL-1020BL-1020 may increase the hypotensive activities of Landiolol.Investigational
BrexpiprazoleLandiolol may increase the orthostatic hypotensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Landiolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Landiolol.Investigational
BucindololLandiolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Landiolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Landiolol.Experimental
BunazosinLandiolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Landiolol.Approved, Investigational
CabergolineLandiolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Landiolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Landiolol.Experimental, Investigational
CarbutamideLandiolol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Landiolol.Approved, Vet Approved, Withdrawn
CarvedilolLandiolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Landiolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Landiolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Landiolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Landiolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Landiolol.Experimental
ChlorpromazineLandiolol may increase the orthostatic hypotensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideLandiolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Landiolol.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Landiolol.Approved
ClozapineLandiolol may increase the orthostatic hypotensive activities of Clozapine.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Landiolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Landiolol.Approved, Investigational
CymarinLandiolol may increase the bradycardic activities of Cymarin.Experimental
DapiprazoleLandiolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DapoxetineThe serum concentration of Landiolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Landiolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Landiolol.Approved
DeslanosideLandiolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Landiolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Vet Approved
DextroamphetamineLandiolol may increase the orthostatic hypotensive activities of Dextroamphetamine.Approved, Illicit
DichlorvosDichlorvos may increase the bradycardic activities of Landiolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Landiolol.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Landiolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Landiolol.Approved, Investigational
DigitoxinLandiolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinLandiolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Landiolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Landiolol.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Landiolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Landiolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Landiolol.Experimental
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Landiolol.Approved
DoxazosinLandiolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinLandiolol may increase the orthostatic hypotensive activities of Doxepin.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Landiolol.Approved
DroperidolLandiolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Landiolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
DuloxetineThe serum concentration of Landiolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Landiolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Landiolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Landiolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Landiolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Landiolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Landiolol.Approved
Ergoloid mesylateLandiolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineLandiolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
EscitalopramLandiolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Landiolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Landiolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Landiolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Landiolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
EtoperidoneThe serum concentration of Landiolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Landiolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Landiolol.Investigational, Nutraceutical
ExisulindExisulind may decrease the antihypertensive activities of Landiolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Landiolol.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Landiolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Landiolol.Approved
FentanylFentanyl may increase the bradycardic activities of Landiolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Landiolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Landiolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Landiolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Landiolol.Experimental
FingolimodLandiolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Landiolol is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Landiolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Landiolol.Experimental
FluoxetineThe serum concentration of Landiolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolLandiolol may increase the orthostatic hypotensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Landiolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Landiolol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Landiolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Landiolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Landiolol.Approved, Investigational, Nutraceutical
GitoformateLandiolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideLandiolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideLandiolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLandiolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLandiolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneLandiolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideLandiolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideLandiolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Landiolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Landiolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
HexobarbitalThe serum concentration of Landiolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Landiolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Landiolol.Approved, Investigational
HydroxychloroquineThe metabolism of Landiolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Landiolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Landiolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Landiolol.Approved, Investigational
IloperidoneLandiolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Landiolol.Experimental
ImipramineLandiolol may increase the orthostatic hypotensive activities of Imipramine.Approved
IndalpineThe serum concentration of Landiolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Landiolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Landiolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Landiolol.Withdrawn
IndoraminLandiolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanLandiolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkLandiolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Landiolol.Experimental
IsoflurophateIsoflurophate may increase the bradycardic activities of Landiolol.Approved, Investigational, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Landiolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Landiolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Landiolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Landiolol.Approved
LabetalolLandiolol may increase the orthostatic hypotensive activities of Labetalol.Approved
Lanatoside CLandiolol may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Landiolol.Approved, Investigational
LevomilnacipranThe serum concentration of Landiolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Landiolol.Approved, Vet Approved
LisdexamfetamineLandiolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Landiolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Landiolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Landiolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Landiolol.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Landiolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Landiolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Landiolol.Approved
MalathionMalathion may increase the bradycardic activities of Landiolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Landiolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Landiolol.Approved, Vet Approved
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Landiolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Landiolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Landiolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Landiolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Landiolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Landiolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Landiolol.Approved, Investigational
MetahexamideLandiolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Landiolol.Approved, Investigational, Withdrawn
MethacholineLandiolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Landiolol.Investigational
MethohexitalThe serum concentration of Landiolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineLandiolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Landiolol.Approved, Investigational
MethylergometrineLandiolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Landiolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinLandiolol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Landiolol.Approved, Investigational
MidodrineLandiolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Landiolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Landiolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Landiolol.Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Landiolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Landiolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Landiolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Landiolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Landiolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Landiolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Landiolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Landiolol.Approved, Vet Approved
NefazodoneLandiolol may increase the orthostatic hypotensive activities of Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Landiolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Landiolol.Approved, Investigational
NicardipineLandiolol may increase the orthostatic hypotensive activities of Nicardipine.Approved, Investigational
NicergolineLandiolol may increase the orthostatic hypotensive activities of Nicergoline.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Landiolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Landiolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Landiolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Landiolol.Approved
NiguldipineLandiolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
NimesulideNimesulide may decrease the antihypertensive activities of Landiolol.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Landiolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
NortriptylineLandiolol may increase the orthostatic hypotensive activities of Nortriptyline.Approved
OlanzapineLandiolol may increase the orthostatic hypotensive activities of Olanzapine.Approved, Investigational
OleandrinLandiolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Landiolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Landiolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Landiolol.Vet Approved
OuabainLandiolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Landiolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Landiolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Landiolol.Experimental, Nutraceutical
ParaoxonParaoxon may increase the bradycardic activities of Landiolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Landiolol.Approved
ParoxetineThe serum concentration of Landiolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Landiolol.Approved, Investigational
PentobarbitalThe serum concentration of Landiolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerazinePerazine may increase the hypotensive activities of Landiolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Landiolol.Approved
PeruvosideLandiolol may increase the bradycardic activities of Peruvoside.Experimental
PhenobarbitalThe serum concentration of Landiolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineLandiolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PhentolamineLandiolol may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Landiolol.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Landiolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Landiolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Landiolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Landiolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Landiolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Landiolol.Experimental
PizotifenLandiolol may increase the orthostatic hypotensive activities of Pizotifen.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Landiolol.Experimental, Investigational
PrazosinLandiolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Landiolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Landiolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Landiolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Landiolol.Experimental
PromazineLandiolol may increase the orthostatic hypotensive activities of Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Landiolol.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Landiolol.Approved, Investigational
PropafenoneThe serum concentration of Landiolol can be increased when it is combined with Propafenone.Approved
PropericiazineLandiolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PropiomazineLandiolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Landiolol.Vet Approved
PropiverineLandiolol may increase the orthostatic hypotensive activities of Propiverine.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Landiolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Landiolol.Experimental
ProscillaridinLandiolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Landiolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Landiolol.Approved, Investigational
QuetiapineLandiolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
QuinidineLandiolol may increase the orthostatic hypotensive activities of Quinidine.Approved, Investigational
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Landiolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Landiolol.Approved
ReserpineReserpine may increase the hypotensive activities of Landiolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Landiolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Landiolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Landiolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Landiolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
RivastigmineLandiolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Landiolol.Approved, Investigational, Withdrawn
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
SalicylamideSalicylamide may decrease the antihypertensive activities of Landiolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Landiolol.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Landiolol.Approved
SecobarbitalThe serum concentration of Landiolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Landiolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Landiolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Landiolol.Investigational
SertralineThe serum concentration of Landiolol can be increased when it is combined with Sertraline.Approved
SilodosinLandiolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SRT501SRT501 may decrease the antihypertensive activities of Landiolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Landiolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Landiolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Landiolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Landiolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Landiolol.Experimental
TacrineTacrine may increase the bradycardic activities of Landiolol.Investigational, Withdrawn
TafenoquineThe metabolism of Landiolol can be decreased when combined with Tafenoquine.Investigational
TamsulosinLandiolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Landiolol.Investigational
TenidapTenidap may decrease the antihypertensive activities of Landiolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Landiolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Landiolol.Vet Approved
TerazosinLandiolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Landiolol.Approved
ThiamylalThe serum concentration of Landiolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Landiolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Landiolol.Withdrawn
ThiopentalThe serum concentration of Landiolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineLandiolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
ThioridazineLandiolol may increase the orthostatic hypotensive activities of Thioridazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Landiolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Landiolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
TolazamideLandiolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineLandiolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideLandiolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Landiolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Landiolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Landiolol.Approved, Investigational
TrazodoneLandiolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Landiolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Landiolol.Vet Approved
TrifluoperazineLandiolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Landiolol.Approved, Vet Approved
TrimazosinLandiolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimipramineLandiolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Landiolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Landiolol.Approved
TyrothricinTyrothricin may increase the bradycardic activities of Landiolol.Approved
UrapidilLandiolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Landiolol.Approved, Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Landiolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Landiolol can be increased when it is combined with Venlafaxine.Approved
VerapamilLandiolol may increase the orthostatic hypotensive activities of Verapamil.Approved
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Landiolol.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Landiolol.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Landiolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Landiolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Landiolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneLandiolol may increase the orthostatic hypotensive activities of Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Landiolol.Withdrawn
ZuclopenthixolLandiolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
114905
PubChem Substance
347828494
ChemSpider
102855
ChEBI
135809
ChEMBL
CHEMBL1742466
Wikipedia
Landiolol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
2CompletedDiagnosticCoronary Artery Disease2
2CompletedTreatmentHealthy Volunteers / Pharmacokinetics/Dynamics Study1
2CompletedTreatmentPostoperative Supraventricular Tachyarrythmia1
2, 3CompletedTreatmentPostoperative Supraventricular Tachyarrythmia1
3CompletedDiagnosticCoronary Artery Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.334 mg/mLALOGPS
logP0.44ALOGPS
logP0.35ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)14.04ChemAxon
pKa (Strongest Basic)8.79ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area127.82 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity131.29 m3·mol-1ChemAxon
Polarizability56.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as morpholine carboxylic acids and derivatives. These are heterocyclic compounds containing a morpholine ring substituted by one or more carboxylic acid groups (or derivative thereof).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Morpholine carboxylic acids and derivatives
Alternative Parents
Phenoxy compounds / Phenol ethers / Ketals / Alkyl aryl ethers / Fatty acid esters / 1,3-dioxolanes / Ureas / Secondary alcohols / 1,2-aminoalcohols / Carboxylic acid esters
show 10 more
Substituents
Morpholine-4-carboxylic acid or derivatives / Phenoxy compound / Phenol ether / Alkyl aryl ether / Ketal / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Benzenoid / Meta-dioxolane
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:37 / Updated on June 02, 2018 09:47